ClinicaliQ Trial Snapshot
- Attachment Inhibitor Comparison in Heavily Treatment Experienced Patients — Active Not Recruiting • Phase III • Infectious Disease • NCT02362503.
- A new HIV drug (BMS-663068) tested in patients with resistant virus who have failed multiple previous treatments.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to determine whether the BMS Attachment Inhibitor (BMS-663068) is effective in the treatment of heavily treatment experienced HIV-1 patients with multi-drug resistance. Conditions: HIV Infections Interventions: BMS-663068, Placebo Lead Sponsor: ViiV Healthcare Planned Enrollment: 371 participants